Dravet Syndrome

A prospective open‐label trial of a CBD/THC cannabis oil in dravet syndrome

PURPOSE The purpose of this study was to establish a dose guideline for pure CBD therapy for seizure reduction. The mean dose of CBD achieved was 13.3 mg/kg/day of CBD (range 7–16 mg/kg/day). Based on the dose measurements below, this would be approximately 1 full dropper of CBD oil from the 500mg bottle of CBD oil. Initial research in …

A prospective open‐label trial of a CBD/THC cannabis oil in dravet syndrome Read More »

Cannabidiol: A New Hope for Patients With Dravet or Lennox-Gastaut Syndromes

ABSTRACT Pure, plant-based CBD is a pharmaceutical grade extract that exhibits clinically significant antiseizure properties, with a hypothesized multimodal mechanism of action. In the GWPCARE trial series, CBD displayed superior efficacy in reducing key seizure frequencies (convulsive seizures in DS; drop seizures in LGS) by 17% to 23% compared with placebo as adjunctive therapy to …

Cannabidiol: A New Hope for Patients With Dravet or Lennox-Gastaut Syndromes Read More »

Long-term cannabidiol treatment in patients with Dravet syndrome: An open-label extension trial

ABSTRACT By November 2016, a total of 278 patients had completed the original randomized trials, and 264 (95%) enrolled in this open-label extension. Median treatment duration was 274 days (range 1-512) with a mean modal dose of 21 mg/kg/d, and patients received a median of 3 concomitant antiepileptic medications. Adverse events (AEs) occurred in 93.2% …

Long-term cannabidiol treatment in patients with Dravet syndrome: An open-label extension trial Read More »

Sign up for SMS offers and we'll send you a coupon code for a free CBD face mask. To join

text "JOIN" to (864) 754-0630 or click the button below.

Free

Gift

CBD Face Mask 10mg CBD Beauty for Acne

BONUS OFFER

of $49 or more

COUPON EXPIRES 2/29/2020 | USE CODE "WELCOMEGIFT" 

FREE WITH PURCHASE

Scroll to Top
{"cart_token":"","hash":"","cart_data":""}